A Double-blind, Intra-individual Comparison, Proof-of-concept Trial of Topical AC-203 in Patients With Inherited Epidermolysis Bullosa

Trial Profile

A Double-blind, Intra-individual Comparison, Proof-of-concept Trial of Topical AC-203 in Patients With Inherited Epidermolysis Bullosa

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Diacerein (Primary)
  • Indications Epidermolysis bullosa
  • Focus Proof of concept; Therapeutic Use
  • Sponsors TWi Biotechnology
  • Most Recent Events

    • 14 Mar 2018 Status changed from planning to not yet recruiting.
    • 28 Feb 2018 New trial record
    • 26 Feb 2018 According to a TWi Biotech media release, the Company has received approval from the Taiwan Food and Drug Administration (TFDA) to proceed this trial and expects the first patient to be enrolled in early Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top